This randomized pilot phase I trial studies the side effects of dietary fat levels and abiraterone acetate uptake in patients with metastatic hormone-resistant prostate cancer. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Eating a low or high fat diet may increase the uptake of abiraterone acetate.
No linked publications found in PubMed
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * About to initiate or currently being treated with abiraterone acetate 1000 mg orally once daily * Clinically able to receive abiraterone acetate in the opinion of the investigator in accordance with standard prescribing practices * Ability to consume a low fat and high fat diet * Expected duration of continuous abiraterone therapy \> 8 weeks * Signed and dated informed consent Exclusion Criteria: * Patients taking medications that strongly inhibit or induce cytochrome P450 (CYP)3A4 within 28 days prior to the start of the study will be excluded